SAN DIEGO & BOSTON--(BUSINESS WIRE)--Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Juniper Pharmaceuticals, Inc. (NASDAQGS: JNP) violated federal securities laws by issuing materially misleading information to the investing public. Juniper Pharmaceuticals focuses on developing therapeutics that address unmet medical needs in women's health.
Juniper Pharmaceuticals Announces Restatement of Financials
On October 24, 2016, Juniper Pharmaceuticals announced in its Form 8-K filed with the U.S. Securities and Exchange Commission that it would have to restate its financial statements since 2013. The company stated that the errors concerned revenue recognition related to a supply agreement with an affiliate of Germany's Merck KGaA. On this news, Juniper Pharmaceuticals stock fell 10% in early morning trading on October 25, 2016.
View this press release on the law firm's Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/juniper-pharmaceuticals-inc
Juniper Pharmaceuticals Shareholders Have Legal Options
Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.
Attorney Advertising. Past results do not guarantee a similar outcome.